Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'
Tweet Send to a Friend
Goldman Sachs analyst Richard Law reiterated a Buy rating and $40.00 price target on Viridian Therapeutic (NASDAQ: VRDN)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
